Biotech · Private company
Adagene Inc
Track this companyFree. Adds Adagene Inc to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- ADG126Phase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ADG126 MonoPhase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ADG126-ADG106Phase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ADG126-anti PD1Phase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ADG106Phase 1 · Solid Tumors, Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ADG106Phase 1 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ADG116Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ADG116Phase 1 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- anti PD1 drugPhase 1 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jun 15, 2022ClinicalTrials.gov NCT05405595 · fetched Nov 12, 2026
- ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsPHASE1 · COMPLETED · started Feb 9, 2022ClinicalTrials.gov NCT05277402 · fetched Nov 12, 2026
- ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid TumorsPHASE1_PHASE2 · COMPLETED · started Mar 15, 2021ClinicalTrials.gov NCT04645069 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 1, 2020ClinicalTrials.gov NCT04524871 · fetched Nov 12, 2026
- A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsPHASE1 · COMPLETED · started Sep 23, 2020ClinicalTrials.gov NCT04501276 · fetched Nov 12, 2026
- Study of ADG116 in Patients With Advanced/Metastatic Solid TumorsPHASE1 · TERMINATED · started Aug 29, 2019ClinicalTrials.gov NCT04111445 · fetched Nov 12, 2026
- Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaPHASE1 · COMPLETED · started Sep 17, 2018ClinicalTrials.gov NCT03707093 · fetched Nov 12, 2026